BR9809381A - Anti-helicobacter vaccine composition comprising a th1-type adjuvant - Google Patents

Anti-helicobacter vaccine composition comprising a th1-type adjuvant

Info

Publication number
BR9809381A
BR9809381A BR9809381-9A BR9809381A BR9809381A BR 9809381 A BR9809381 A BR 9809381A BR 9809381 A BR9809381 A BR 9809381A BR 9809381 A BR9809381 A BR 9809381A
Authority
BR
Brazil
Prior art keywords
helicobacter
vaccine composition
type adjuvant
adjuvant
type
Prior art date
Application number
BR9809381-9A
Other languages
Portuguese (pt)
Inventor
Jean Haensler
Bruno Guy
Original Assignee
Merieux Oravax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9705608A external-priority patent/FR2762787B1/en
Application filed by Merieux Oravax filed Critical Merieux Oravax
Publication of BR9809381A publication Critical patent/BR9809381A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

<B>COMPOSIçãO DE VACINA ANTI-HELICOBACTER COMPREENDENDO UM ADJUVANTE DO TIPO TH1<D> O tema da invenção é o uso de um agente imunogênico derivado de Helicobacter, em combinação com um adjuvante como QS-21, DC-chol ou Bay R1005, na fabricação de uma composição farmacêutica destinada à indução de uma resposta imune do tipo T auxiliar 1 (Th1) contra Helicobacter, para evitar ou tratar uma infecção por Helicobacter em um mamífero.<B> ANTI-HELICOBACTER VACCINE COMPOSITION UNDERSTANDING A TH1 TYPE ADJUVANT <D> The subject of the invention is the use of an immunogenic agent derived from Helicobacter, in combination with an adjuvant such as QS-21, DC-chol or Bay R1005, in the manufacture of a pharmaceutical composition intended to induce an auxiliary T-type 1 (Th1) immune response against Helicobacter, to prevent or treat a Helicobacter infection in a mammal.

BR9809381-9A 1997-04-30 1998-04-30 Anti-helicobacter vaccine composition comprising a th1-type adjuvant BR9809381A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9705608A FR2762787B1 (en) 1997-04-30 1997-04-30 ANTI-HELICOBACTER VACCINE COMPOSITION COMPRISING A TH1 ADJUVANT
FR9715732 1997-12-08
PCT/FR1998/000875 WO1998048836A1 (en) 1997-04-30 1998-04-30 Anti-helicobacter vaccine composition comprising a th1 adjuvant

Publications (1)

Publication Number Publication Date
BR9809381A true BR9809381A (en) 2000-07-04

Family

ID=26233513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809381-9A BR9809381A (en) 1997-04-30 1998-04-30 Anti-helicobacter vaccine composition comprising a th1-type adjuvant

Country Status (7)

Country Link
EP (1) EP0979100A1 (en)
JP (1) JP2002505665A (en)
KR (1) KR20010020418A (en)
AU (1) AU750379B2 (en)
BR (1) BR9809381A (en)
CA (1) CA2287976A1 (en)
WO (1) WO1998048836A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781160B1 (en) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc USE OF AN AMPHIPATHIC COMPOUND TO ADJUST A SUBUNIT VACCINE
EP1229925A2 (en) * 1999-11-19 2002-08-14 Axxima Pharmaceuticals Aktiengesellschaft Inhibitors of helicobacter pylori induced gastrointestinal diseases
GB0008877D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
GB0008879D0 (en) * 2000-04-12 2000-05-31 Astrazeneca Ab Polypeptide delivery system
WO2002005845A1 (en) * 2000-07-05 2002-01-24 Merieux Oravax Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
US6849409B2 (en) 2000-10-16 2005-02-01 Axxima Pharmaceuticals Ag Cellular kinases involved in Cytomegalovirus infection and their inhibition
JP2004528321A (en) * 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ Polynucleotide binding complexes containing sterols and saponins
JP2012171914A (en) * 2011-02-22 2012-09-10 Kao Corp Gip increase inhibitor
RU2736642C2 (en) * 2015-07-20 2020-11-19 Зоэтис Сервисиз Ллс Liposomal adjuvant compositions
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3521994A1 (en) * 1985-06-20 1987-01-02 Bayer Ag N- (2-AMINOACYLAMIDO-2-DESOXY-HEXOSYL) -AMIDES, CARBAMATES AND UREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
FR2732605B1 (en) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc COMPOSITION FOR INDUCING MUCOSAL IMMUNE RESPONSE

Also Published As

Publication number Publication date
AU7658498A (en) 1998-11-24
AU750379B2 (en) 2002-07-18
WO1998048836A1 (en) 1998-11-05
CA2287976A1 (en) 1998-11-05
EP0979100A1 (en) 2000-02-16
JP2002505665A (en) 2002-02-19
KR20010020418A (en) 2001-03-15

Similar Documents

Publication Publication Date Title
BRPI9609414B8 (en) combination of vaccine and kit to produce the same.
BR9915988A (en) S5 streptococcal peptidase vaccine
BR9809381A (en) Anti-helicobacter vaccine composition comprising a th1-type adjuvant
NO20005051L (en) Adjuvantsammensetninger
BR9911482A (en) Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
ES2195169T3 (en) VACCINES AGAINST CALMIDIES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN EXTERNAL MEMBRANE ANTIGEN AND METHODS FOR PREPARATION.
BR0014285A (en) Adjuvants comprising a polyoxyethylene alkyl ester or ether and at least one nonionic surfactant
ES2176232T3 (en) ADEQUATE VACCINE TO BE USED IN THE PREVENTION AND TREATMENT OF INFECTION WITH HELICOBACTER.
UA40597C2 (en) Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
ATE116993T1 (en) SAPONIN REMEDIES.
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
BRPI0007936B8 (en) compound, immunological adjuvant formulation, and vaccine formulation.
NO20082472L (en) Vaccine compositions comprising a saponin adjuvant
DE69818707D1 (en) CHITOSAN AND INFLUENZA-ANTIGEN (S) CONTAINING VACCINE PREPARATIONS FOR ADMINISTRATION BY A MUCOSA
HUP0301180A2 (en) Use of immidazoquinolinamines as adjuvants in dna vaccination
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR0213358A (en) Flibanserin use
BR0108828A (en) Carbohydrate formulation (prebiotic adjuvant) for enhancing immune response
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
BR0114392A (en) Vaccine formulation, method for producing a vaccine formulation, use of a divided rsv vaccine preparation, kit for releasing an intranasal vaccine formulation, intranasal release device, and method for protecting or treating a mammal susceptible to, or suffering from rsv disease
UY24654A1 (en) COMPOSITION OF VACCINE AGAINST MALARIA
BR112023002932A2 (en) ADENOVIRUS VECTORS AND METHODS FOR USING ADENOVIRUS VECTORS
PT854924E (en) LEISHMANIA ANTIGENS FOR USE IN LEISHMANIOSE THERAPY AND DIAGNOSIS
BR0316244A (en) Polynucleotide vaccine, methods of preventing or treating an hcv infection in a mammal and vaccinating an individual, and use of a polynucleotide vaccine
BRPI0416376A (en) compositions for reducing bacterial colonization and snc invasion and methods of using these

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1912 DE 28/08/2007.